DailyDoctor Archive Specialties Get app
All paediatrics briefings

The edition · Paediatrics

Short antibiotic courses for childhood pneumonia and sinusitis rose from 13% to 65% with a pathway and prompts

A US paediatric emergency department improvement project shows how guideline durations get adopted, without more return visits. Also: levetiracetam against valproate in childhood epilepsy, and a consensus on recognising dysfunctional breathing.

The edition in brief

A quality improvement project in Pediatrics, published on 13 October, raised the share of children discharged from one US paediatric emergency department with community-acquired pneumonia or acute bacterial sinusitis on a guideline-recommended short antibiotic course from 13.1% to 64.8%. The tools were a clinical pathway, electronic record changes, prescriber education and feedback. Return visits within 14 days did not rise. Current guidance supports 3 to 5 days for uncomplicated pneumonia and 5 to 7 days for sinusitis. A meta-analysis of eight randomised trials and 1,000 children found no significant difference in seizure freedom between levetiracetam and valproate (RR 0.95, 95% CI 0.83 to 1.09), with low-certainty evidence; levetiracetam had fewer adverse events and less weight gain. Time-to-event outcomes favoured valproate but were exploratory. A UK eDelphi of paediatric respiratory experts agreed ten clinical features consistent with dysfunctional breathing in children and young people, a first step towards a validated assessment tool. The pearl covers telling dysfunctional breathing from asthma.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for paediatrics, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free